UCB reports positive data from BE READY trial of bimekizumab
UCB intends to seek regulatory approval mid next year for bimekizumab in adults with moderate-to-severe plaque psoriasis. Credit: UCB S.A.
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.ContinueLearn more